Topical wet AMD therapy passes first test with success
A Phase I clinical study of Athenagen's topical eye drop therapy for wet age-related macular degeneration (AMD), ATG3, has found it to be safe and well tolerated.
A Phase I clinical study of Athenagen's topical eye drop therapy for wet age-related macular degeneration (AMD), ATG3, has found it to be safe and well tolerated.
The randomized, double-masked, placebo-controlled study enrolled 80 healthy subjects to receive single and multiple dose ascending regimens for up to two weeks. No medication-related systemic side effects were noted and the therapy demonstrated good ocular tolerability.
A Phase II trial is expected to be initiated soon and will be a placebo-controlled, double-masked, randomized dose-ranging study, evaluating both safety and efficacy.
